SGLT2 inhibitors and GLP-1 receptor agonists: which is the best anti-frailty drug?
Pasquale Mone, Michele Ciccarelli, Stanislovas S. Jankauskas, Germano Guerra, Carmine Vecchione, Valeria Visco, Gaetano Santulli
Topics & Concepts
DrugPharmacologyGlucagon-like peptide 1 receptorMedicineReceptorChemistryAgonistInternal medicineDiabetes Treatment and ManagementFrailty in Older AdultsNutrition and Health in Aging